Lisata Therapeutics, Inc. (LSTA) is a biopharmaceutical firm focused on developing innovative treatments that significantly improve the outcomes of serious diseases. The company aims to create a new paradigm of patient care with precise, individualized therapies utilizing the latest advancements in genetic and molecular medicine.
Based in the United States, LSTA is committed to advancing therapeutic areas by applying a unique, patient-centric approach. This involves bridging the gap between molecular biology knowledge and clinical applications, in order to bring novel, transformational therapies to patients who need them.
The company's comprehensive portfolio spans programs in areas of considerable unmet medical need, such as cancer, cardiovascular diseases, and other serious conditions. LSTA works on harnessing the body's innate capabilities to fight diseases, with the potential to dramatically change patients' lives by offering treatments that previously seemed inconceivable.
LSTA marks a compelling blend of talented scientists, experienced management, and cutting-edge technology. These resources, coupled with a strong focus on translational science and clinical development, allow the company to effectively translate groundbreaking scientific discoveries into proven medical treatments.
Central to LSTA's scientific ethos is an unwavering commitment to rigorous R&D. By investigating the fundamental processes driving disease pathogenesis, the company aspires to discover breakthrough therapies that can transform disease understanding and treatment protocols.
Of equal importance to the company's innovation-focused approach is its commitment to ethical conduct. LSTA makes every effort to ensure its research and processes uphold the highest standards of integrity, transparency, and patient wellbeing. Above all, the company prioritizes the health and well-being of the patients relying on its products.
LSTA is driven by the fundamental belief that every patient deserves a unique, targeted therapy that maximizes their chances of conquering their disease. In addition to its own robust drug pipeline, LSTA actively seeks out partnerships and collaborations that will accelerate the development and delivery of these promising therapies. By doing so, it strives to achieve its mission of transforming lives through the power of precision, targeted healthcare.
While still relatively early in its development journey, LSTA is well-positioned to make significant strides within the pharmaceutical industry. With a scientific foundation built on genomics and molecular biology and a corresponding focus on capitalizing on the latest advancements in these fields, Lisata Therapeutics, Inc. is at the cutting edge of medical innovation. As the company continues to grow and evolve, it remains steadfastly focused on its fundamental goal: creating transformative therapies that significantly improve patient outcomes.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends

Marea Therapeutics announced positive results from Part A of its Phase 2b TYDAL-TIMI 78 trial for MAR001, showing significant reductions in triglycerides (39.1%-45.5%) without worsening glycemic control. The drug, a potential first-in-class ANGPTL4 inhibitor, demonstrated even greater efficacy in participants with higher baseline triglyceride levels. These findings, presented at AHA 2026 and published in NEJM, support MAR001/MAR005 as a promising treatment for severe hypertriglyceridemia, with Part B of the trial now enrolling.

Marea Therapeutics, a subsidiary of Lisata Therapeutics, announced its participation in several upcoming investor conferences in November. Management will present at the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference London, with live webcasts available for both. The company, which focuses on developing medicines for cardioendocrine diseases, will also hold 1x1 meetings at the LifeSci Growth and Innovation Summit.
This small cap wrap covers news from several companies including Nextech3D.ai, which has added agentic AI to its Map D software, and Nine Mile Metals, which reported high-grade VMS mineralization at its Wedge Mine. Lisata Therapeutics has appointed a new finance executive to its board, while Dune Oil Corp reached a settlement for a US$3.68 million loan. Additionally, Horizon Gold, First Graphene, Noble Helium, Standard Uranium, Snail Inc, Gana Media Group, Anglo Asian Mining Plc, and DroneShield Ltd are featured for their recent developments and financial updates.